Expansion of new US patent on Cyclophilin Inhibitor program by Contravir Pharmaceuticals

On 27th August 2017 a biopharmaceutical company Contravir pharmaceutical gets the new US patent issuance on the expansion program of the drug (CRV 431) Cyclophilin inhibitor used for the treatment of hepatitis B virus (HBV) with the US patent no. 9,741,271. The company also says that CRV 431 can also be used in conjunctions with [...]